First published evidence showing that individual fetal fraction measurement is a critical determinant of test reliability
SAN CARLOS, Calif., Nov. 27, 2019 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced results of a study published in the Journal of Prenatal Diagnosis which demonstrated that measuring individual fetal fractions combined with reporting zygosity provides clinically powerful insights into the accuracy of the aneuploidy results.1 Panorama® remains the only non-invasive prenatal test (NIPT) that reports zygosity for twins, and individual fetal fractions for dizygotic pregnancies.2 The study examined Panorama results from a cohort of 126,061 pregnancies, of which 3.7% were twin pregnancies. The study represents the first published evidence that DNA contribution from each twin in dizygotic pregnancies can vary widely. When the fetal fractions are discrepant, the signal from the dominant twin obfuscates the signal from the other twin. Consequently, NIPTs that only provide a combined fetal fraction and do not assess individual fetal fraction in dizygotic twin pregnancies may not detect a condition in the non-dominant twin, and can increase the risk of false negatives. “The ability to accurately determine zygosity in twin pregnancies, and individual fetal fraction in dizygotic pregnancies, is a major advancement in the management of twin pregnancies,” said Paul Billings, M.D., Ph.D., Natera’s Chief Medical Officer. “NIPTs that do not report both zygosity and individual fetal fraction may be less reliable in assessing the risk of aneuploidies in certain twins.” “Panorama’s SNP technology has unique advantages, including our twins assessment, that are unmatched by other methods. Although twin pregnancies comprise approximately 3-4% of all pregnancies, this new finding is clinically significant and may help us serve new physicians in offices where we do not have a presence today,” said Steve Chapman, Natera’s Chief Executive Officer. “We are proud of our accomplishment of reaching 20 publications on Panorama covering a total of more than 1.2 million patients. We believe that the combination of our highly differentiated assay and market-leading portfolio of data is contributing to our continued strong growth.” The study, titled “Cell-free DNA fetal fraction in twin gestations in single-nucleotide polymorphism-based noninvasive prenatal screening” can be found here. About Panorama® This test was developed by Natera, Inc., a laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). This test has not been cleared or approved by the U.S. Food and Drug Administration (FDA). Although FDA does not currently clear or approve laboratory-developed tests in the U.S., certification of the laboratory is required under CLIA to ensure the quality and validity of the tests. About Natera Forward-Looking Statements Natera Contacts References
View original content to download multimedia:http://www.prnewswire.com/news-releases/panorama-publication-demonstrates-utility-of-measuring-individual-fetal-fractions-in-twin-pregnancies-300965971.html SOURCE Natera, Inc. | ||
Company Codes: NASDAQ-NMS:NTRA |